Related Experiment Video

Updated: Jan 12, 2026

Click-Chemistry Based Fluorometric Assay for Apolipoprotein N-acyltransferase from Enzyme Characterization to High-Throughput Screening
07:37

Click-Chemistry Based Fluorometric Assay for Apolipoprotein N-acyltransferase from Enzyme Characterization to High-Throughput Screening

Published on: May 13, 2020

2.3K

ANGPTL3/8: one target, multiple lipid disorders

Ren Zhang1

  • 1Center for Molecular Medicine and Genetics, Wayne State University Medical School, Detroit, MI 48202, USA.

Trends in Molecular Medicine
|October 30, 2025
PubMed

Insights

Selective blockade of the angiopoietin-like protein (ANGPTL)3/8 complex effectively lowers triglycerides and raises HDL-cholesterol. This approach shows promise as a precision therapy for various dyslipidemias.

Area of Science:

  • Biochemistry and Molecular Biology
  • Cardiovascular Medicine
  • Metabolic Disorders

Background:

  • The angiopoietin-like protein (ANGPTL)3/8 complex is a key regulator of triglyceride metabolism.
  • Dyslipidemia, characterized by abnormal lipid levels, is a major risk factor for cardiovascular disease.
  • Current therapies have limitations in addressing complex lipid disturbances.

Purpose of the Study:

  • To evaluate the therapeutic potential of selectively blocking the ANGPTL3/8 complex.
  • To investigate the impact of ANGPTL3/8 antagonism on triglyceride and HDL-cholesterol levels.
  • To explore ANGPTL3/8 antagonism as a precision medicine approach for dyslipidemias.

Main Methods:

  • Inhibition of the ANGPTL3/8 complex.
  • Assessment of lipid partitioning.
  • Analysis of clinical and genetic data related to dyslipidemia.

Main Results:

  • Selective blockade of ANGPTL3/8 complex leads to reduced triglyceride levels.
  • HDL-cholesterol levels are increased following ANGPTL3/8 blockade.
  • Evidence supports ANGPTL3/8 antagonism for conditions like mixed dyslipidemia and monogenic hypertriglyceridemia.

Conclusions:

  • ANGPTL3/8 antagonism represents a promising therapeutic strategy for dyslipidemia.
  • This approach offers a precision therapy by correcting fundamental lipid partitioning disturbances.
  • Further research supports its application in genetic and acquired dyslipidemias.
Keywords:
ANGPTL3ANGPTL8APOA5CREBHtriglyceride

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.3K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.7K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.8K
Lipids as Anchors01:32

Lipids as Anchors

In the plasma membrane, the lipids forming the bilayer can also act as an anchor to tether proteins to the membrane. The three main types of lipid anchors found in eukaryotes are – prenyl groups, fatty acyl groups, and glycosylphosphatidylinositol or GPI groups. Prenyl and fatty acyl groups act as anchors on the cytosolic surface of the membrane, whereas GPI anchors proteins on the extracellular side.
The carboxy-terminal of most of the prenylated proteins, such as Ras proteins, contains...
7.1K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
311